TissueTech Names New Vice President to Lead Human Resources Operations and Process Improvement Initiatives
Miami, FL – October 2, 2019– TissueTech,™ Inc., a pioneer and market leader in the development and clinical application of human birth tissue products, today announced the appointment of Kim Tripodo to the role of Vice President of Human Resources. In this role, Ms. Tripodo will be responsible for all aspects of human resource functions and employee-related initiatives.
Ms. Tripodo holds oversight for providing overall direction and guidance to TissueTech’s Human Resources department including talent acquisition, training and development, compensation and benefits, succession planning, and diversity training. Additionally, she is responsible for working with the Executive Leadership team to ensure that the Company’s goals and key objectives are met.
“TissueTech is undergoing a significant amount of transformational change at this time. Kim’s experience in leading high growth organizations through this type of migration will be invaluable,” said Michael Cornelius, Chief Financial Officer. “She is a welcome addition to our leadership team.”
Ms. Tripodo brings more than 20 years of executive-level leadership experience to TissueTech. Prior to joining the organization, she served as Vice President of Human Resources for Harvard Maintenance, Inc., Vice President of Human Resources for Health Science Communications (an Omnicom Company), and Director of Human Resources for ChenMed, LLC. She obtained her bachelor’s degree in business administration with a concentration in Human Resources Management from the Joseph I. Lubin School of Business at Pace University and Master of Science degree in Human Resources Education from Fordham University.
“Building solid process improvement initiatives is critical to the success of any growth-oriented organization,” said Tripodo. “I am proud to contribute to this process. It is a wonderful opportunity for TissueTech and our employees.”
About TissueTech, Inc.
TissueTech is a scientific and market leader in the field of regenerative medicine. TissueTech manufactures a broad range of ocular, surgical, wound care and soft tissue products to support regenerative tissue healing using amniotic membrane and umbilical cord birth tissue donated from healthy, pre-screened mothers after elective cesarean section delivery of a live birth. The organization brings a skilled approach to innovation in evidence-based medicine with more than 20 years of clinical experience and more than 30 years of scientific research funded by the National Institutes of Health. TissueTech is committed to an unwavering culture of integrity that places our patients’ safety and clinical outcomes above all else. Learn more at www.tissuetech.com.